<SEC-DOCUMENT>0001628280-26-024819.txt : 20260413
<SEC-HEADER>0001628280-26-024819.hdr.sgml : 20260413
<ACCEPTANCE-DATETIME>20260413061720
ACCESSION NUMBER:		0001628280-26-024819
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260413
FILED AS OF DATE:		20260413
DATE AS OF CHANGE:		20260413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231
		LEGAL ENTITY IDENTIFIER:    	9695002Y8420ZB8HJE29

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		26856376

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6k-iphx260413.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ifdacc6579340488d99c5f5691351e79a_1"></div><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.55pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="margin-top:0.1pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-top:0.1pt;padding-left:199.2pt;padding-right:199.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:218%">Washington, D.C. 20549 FORM 6-K</font></div><div style="margin-top:0.5pt;padding-left:6.82pt;padding-right:6.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:240%">Date of report&#58; Thursday April 13, 2026</font></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:240%">Commission File Number&#58; 001-39084</font></div><div style="margin-top:0.05pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma S.A.</font></div><div style="margin-top:0.45pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">(Translation of registrant's name into English)</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma S.A.</font></div><div style="margin-top:0.4pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">117 Avenue de Luminy&#8212;BP 30191</font></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">13009 Marseille, France</font></div><div style="margin-top:0.45pt;padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">+ 33 (0) 4 30 30 30</font></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">(Address of principal executive office)</font></div><div style="margin-top:0.25pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Indicate  by  check  mark  whether  the  registrant  files  or  will  file  annual  reports  under  cover  of  Form 20-F or Form 40-F. Form 20-F &#91; X &#93;&#160;&#160;&#160;&#160;Form 40-F &#91; &#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.45pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">EXHIBIT INDEX</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%;text-decoration:underline">Description</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:7.75pt"><font style="color:#0066cc;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">99.1</font><font style="color:#0066cc;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit991-260413.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release dated April 1</a><a href="exhibit991-260413.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">3</a><a href="exhibit991-260413.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">, 202</a><a href="exhibit991-260413.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">6</a></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ifdacc6579340488d99c5f5691351e79a_4"></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.55pt;padding-right:14.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:280.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">INNATE PHARMA S.A.</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:280.1pt;padding-right:5.8pt;text-indent:-274.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:125%">Date&#58; April 13, 2026&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47; JONATHAN DICKINSON&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:125%"> Name&#58;&#160;&#160;&#160;&#160;Jonathan Dickinson</font></div><div style="padding-left:333.15pt;text-indent:-53.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.05pt;font-weight:400;line-height:9.05pt">Title&#58;&#160;&#160;&#160;&#160;Chief Executive officer</font></div><div style="margin-top:0.45pt;padding-left:247.85pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991-260413.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i9b0c6d61f9e34750ac93c6f863e71e1c_1"></div><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.4pt;padding-right:5.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">EXHIBIT 99.1</font></div><div style="margin-top:0.45pt;text-align:center"><font><br></font></div><div style="margin-top:0.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON MAY 21, 2026</font></div><div style="margin-top:0.45pt;text-align:center"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Marseille, France, April 13, 2026, 7&#58;00 AM CEST</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Innate Pharma SA (Euronext Paris&#58; IPH&#59; Nasdaq&#58; IPHA) (&#8220;Innate&#8221; or the &#8220;Company&#8221;) will hold its Annual General Meeting of shareholders (&#8220;AGM&#8221;) at 10&#58;30 a.m. CEST on May 21, 2026, at its headquarters, 117 avenue de Luminy, 13009 Marseille.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">The notice of meeting for this AGM was published on April 13, 2026 in the French Bulletin des annonces l&#233;gales obligatoires (BALO). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Documents and information relating to the AGM will be made available to shareholders in compliance with current regulations on the Investors section of the Company's website. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">**** </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">The AGM will also be broadcast live and accessible at the following link&#58;  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Innate Pharma 2026 Annual General Meeting </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">A guided tour of the Company's laboratories will be organized on the same day at 9&#58;15 a.m. CEST for shareholders. Shareholders can register for the tour via the following link&#58; registration form. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">**** </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Further information regarding the AGM&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Only shareholders who have registered their shares in an account at least five trading business days prior to the date of the AGM, i.e. May 14, 2026, at 00&#58;00 (Paris time), will be entitled to attend the General Meeting. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Shareholders holding &#8220;au porteur&#8221; (bearer) shares will need to obtain an &#8220;attestation de participation&#8221; (certificate of shareholding) from their brokers. This &#8220;attestation de participation&#8221; must be attached to the voting or proxy form. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Written questions from shareholders must be received no later than four business days prior to the AGM, i.e. May 15, 2026, at the following address&#58; investors&#64;innate-pharma.fr. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Shareholders can also obtain the documents and information relating to the AGM (as described in Article R. 225-83 of the French Commercial Code) by sending a request by e-mail to investors&#64;innate-pharma.fr. </font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">About Innate Pharma</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Innate Pharma is advancing a portfolio of differentiated potential first and&#47;or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Information about Innate Pharma shares</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">ISIN code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%"> FR0010331421</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Ticker code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%"> Euronext&#58; IPH Nasdaq&#58; IPHA</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">LEI</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%"> 9695002Y8420ZB8HJE29</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Disclaimer on forward-looking information and risk factors</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">For a discussion of risks and uncertainties, please refer to the Risk Factors (&#8220;Facteurs de Risque&#34;) section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http&#58;&#47;&#47;www.amf-france.org or on Innate Pharma&#8217;s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company&#8217;s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%">For additional information, please contact&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%">Investors  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%">investors &#38; Media Relations </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%">Innate Pharma&#8239; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%">&#8239;St&#233;phanie Cornen&#8239; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">stephanie.cornen&#64;innate-pharma.fr&#8239; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%">Investor Relations&#8239; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">investors&#64;innate-pharma.fr&#8239; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%">Media&#8239; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:100%">communication&#64;innate-pharma.fr&#8239; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
